Clinical Trial Details
| Trial ID: | L1041 |
| Source ID: | NCT00212758 |
| Associated Drug: | Nutropin Aq |
| Title: | A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT00212758/results |
| Conditions: | Kidney Failure, Chronic|Growth Hormone Deficiency |
| Interventions: | DRUG: Nutropin AQ |
| Outcome Measures: | Primary: The Change in Amount of Insulin Like Growth Factor (IGF-I) Generated (Day 8-day 1), We will measure the amount of serum IGF-I generated after 7 days of growth hormone therapy (Day8-Day1)., Day 1 & Day 8 | Secondary: Change in Height at 56 Weeks, week 1, week 56 |
| Sponsor/Collaborators: | Sponsor: Oregon Health and Science University | Collaborators: Genentech, Inc. |
| Gender: | ALL |
| Age: | CHILD, ADULT |
| Phases: | PHASE4 |
| Enrollment: | 17 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: DIAGNOSTIC |
| Start Date: | 2005-01 |
| Completion Date: | 2010-05 |
| Results First Posted: | 2011-10-26 |
| Last Update Posted: | 2011-10-26 |
| Locations: | Loma Linda UMC & Children's Hospital, Loma Linda, California, 92350, United States|University of California in Los Angeles (UCLA), Los Angeles, California, 90095-1752, United States|Stanford University Medical Center, Stanford, California, 94305-5208, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, 97227, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|UT Houston Medical School, Houston, Texas, 77030, United States|University of Washington, Children's Hospital & Regional Medical Center, Seattle, Washington, 98105, United States |
| URL: | https://clinicaltrials.gov/show/NCT00212758 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|